Answer:
A. maintain a minimum average of 80% on all exams
Explanation:
Answer:
C3 plants would have faster growth rates; C4 plants would be minimally affected.
Explanation:
C3 and C4 pathways are the variations of dark reactions of photosynthesis present in green plants. The photosynthetic efficiency of C3 plants is reduced due to the affinity of RuBisCo enzyme for oxygen which in turn leads to the futile pathway of photorespiration. RuBisCo enzyme catalyzes the rate-limiting reaction of the C3 pathway. On the other hand, the C4 plants concentrate CO2 around RuBisCo in their bundle sheath cells of leaves to minimize photorespiration and exhibit higher rates of photosynthesis.
Increased levels of atmospheric CO2 would reduce the photorespiration in C3 plants and would allow them to fix CO2 efficiently due to the increased concentration of CO2 around the enzyme RuBisCo. The increased photosynthetic efficiency would help these plants to exhibit faster growth rates.
However, the photosynthetic rate of C4 plants is not limited by CO2 concentration as they themselves reduce photorespiration by spatial separation of primary carboxylation in mesophyll cell and CO2 fixation in bundle sheath cells. Hence, increased CO2 levels in the atmosphere would not have any impact on their photosynthetic rate and growth.
Answer:
There is growing evidence to indicate that age-related declines in growth hormone (GH), insulin-like growth factor (IGF)-1, and androgen and estrogen production play a role in the pathogenesis of sarcopenia (an age-related decline in muscle mass and quality). Although GH supplementation has been reported to increase lean body mass in elderly individuals, the high incidence of adverse effects combined with a very high cost has limited the applicability of this form of therapy. The assessment of an alternative approach to enhance the GH/IGF-1 axis in the elderly by using GH-releasing hormone and other secretagogues is currently under way and is showing some promise. Testosterone replacement therapy may increase muscle mass and strength and decrease body fat in hypogonadal elderly men. Long-term randomised, controlled trials are needed, however, to better define the risk-benefit ratio of this form of therapy before it can be recommended. Available data are currently insufficient to decide what role estrogen replacement therapy may play in the management of sarcopenia. Therefore, although the evidence linking age-related hormonal changes to the development of sarcopenia is rapidly growing, it is still too early to determine the clinical utility of hormonal supplementation in the management of sarcopenia.
They will start to get very mushy, but they will stay at room temperature.
